Trial Profile
A Randomized, Double-blind, Placebo-controlled Study to Determine Time to Onset of Suppression of the Bone Resorption Marker sCTX With Once Monthly Ibandronate in the Treatment of Postmenopausal Osteoporosis
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 18 Jul 2023
Price :
$35
*
At a glance
- Drugs Ibandronic acid (Primary) ; Calcium supplements; Vitamin D
- Indications Postmenopausal osteoporosis
- Focus Therapeutic Use
- Sponsors Roche
- 09 Sep 2009 Primary endpoint 'Carboxyterminal extension peptide of type I' has been met.
- 09 Sep 2009 Results have been reported in Osteoporosis International.
- 17 Feb 2009 Actual end date changed from 1 Dec 2006 to 1 jul 2007, as reported by ClinicalTrials.gov.